KDR and ovarian carcinoma: Studies show that FBN1 regulates glycolysis and angiogenesis through activation of the vascular endothelial growth factor receptor 2 (VEGFR-2)/STAT2 pathway, decreases the sensitivity of ovarian cancer to cisplatin and promotes chemoresistance in ovarian cancer (Wang Z. et al., 2022).